Renhuang Pharmaceuticals Rated ‘Outperform’ Target Price $7.00 by Beacon Equity Research

Renhuang Pharmaceuticals (OTCBB: RHGP) has been rated Outperform with a price target of $7.00 by Beacon Equity Research Analyst, Lisa Springer, CFA.

The full report is available at http://www.beaconequityresearch.com/

Anyone interested in receiving alerts regarding Renhuang Pharmaceuticals research should email members@beaconequityresearch.com with “RHGP” in the subject line.

In the report, the analyst writes, “Renhuang Pharmaceuticals Inc. (RHGP) is a vertically integrated developer, manufacturer and distributor of high-quality nutraceutical, natural medicinal and bio-pharmaceu­tical products in mainland China. It offers three major product lines: Acanthopa­nax-based natural medicinal products, the Shark Power healthcare series and Tra­ditional Chinese Medicines, which currently represent 50%, 20% and 30% of sales, respectively.

“Renhuang has established a multi-channel research and development infrastructure in China consisting of some 50 in-house researchers and engineers, a post-doctoral work center approved and supported by the Chinese government, and col­laborations with leading institutions and scientists.”

Beacon Equity Research Disclosure

The analysts contributing to this report do not hold any shares of Renhuang Pharmaceuticals (RHGP) Additionally the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. The analyst(s) writing this report recognize and aspire to all of the CFA Institute Guidelines for Independent Research. Beacon Equity Research (“Beacon”) certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analysts in the report. Beacon Equity Research and its affiliates have been directly compensated a total of ten thousand restricted rule 144 shares from Viking Investments for enrollment of RHGP in its research program. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change.